Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine. (10th October 2019)

• Record Type: Journal Article
• Authors: Ha, Jongmok; Na, Boo Suk; Ahn, Jong Hyeon; Kim, Minkyeong; Kim, Jae Woo; Lee, Jae Hyeok; Cho, Jin Whan; Kim, Ji Sun; Youn, Jinyoung
• Is Part Of: Tremor and other hyperkinetic movements. Volume 9(2019)
• Publication Date: 2019-10-10
• Subjects: Paraneoplastic -- autoimmune -- CRMP5 -- CV2 -- chorea; Tremor -- Periodicals; Hyperkinesia -- Periodicals; 616.8
• DOI: 10.7916/tohm.v0.701
• Languages: English
• ISSNs: 2160-8288

Abstract

Background: Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder. The mainstay of treatment is managing the underlying neoplasm. However, the clinical course may be variable, and effective symptomatic management can precede the start of cancer treatment. Case report: A 63-year-old man presented with insidious onset, slowly progressive generalized chorea for 1 year, later diagnosed as anti-CV2/CRMP5 autoantibody positive paraneoplastic chorea. His chorea was markedly improved with intravenous amantadine. Discussion: In patients with anti-CV2/CRMP5 autoantibody-related chorea, sequential follow-up of brain magnetic resonance imaging reveals progression from active inflammation to atrophy. Our report highlights the efficacy of intravenous amantadine in paraneoplastic chorea.